MXPA04001258A - Activador para el receptor d que responde al proliferador de peroxisoma. - Google Patents

Activador para el receptor d que responde al proliferador de peroxisoma.

Info

Publication number
MXPA04001258A
MXPA04001258A MXPA04001258A MXPA04001258A MXPA04001258A MX PA04001258 A MXPA04001258 A MX PA04001258A MX PA04001258 A MXPA04001258 A MX PA04001258A MX PA04001258 A MXPA04001258 A MX PA04001258A MX PA04001258 A MXPA04001258 A MX PA04001258A
Authority
MX
Mexico
Prior art keywords
activator
delta
peroxisome proliferator
hydrogen
responsive receptor
Prior art date
Application number
MXPA04001258A
Other languages
English (en)
Inventor
Masui Seiichiro
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of MXPA04001258A publication Critical patent/MXPA04001258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Abstract

Un compuesto representado por la siguiente formula (I) general: (I) (en donde R1 representa opcionalmente fenilo sustituido, etc.; R2 representa alquilo con C1-4, etc; A representa oxigeno, etc.; X representa una cadena de alquileno con C1-8, etc.; Y representa C (=O), etc.; R3, R4 y R5 representan cada uno hidrogeno, alquilo con C1-4, etc.; B representa CH, etc.; Z representa oxigeno o azufre; R6 y R7 representan cada uno hidrogeno, etc.; y R8 representa hidrogeno, etc.; siempre que al menos uno de R3, R4 y R5 no sea hidrogeno) o una sal del compuesto; y un activador PPAR-d que contiene el compuesto o la sal como el ingrediente activo.
MXPA04001258A 2001-08-10 2002-08-02 Activador para el receptor d que responde al proliferador de peroxisoma. MXPA04001258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001243734 2001-08-10
PCT/JP2002/007897 WO2003016291A1 (fr) 2001-08-10 2002-08-02 Activateur du recepteur $g(d) sensible au proliferateur de peroxysome

Publications (1)

Publication Number Publication Date
MXPA04001258A true MXPA04001258A (es) 2005-06-06

Family

ID=19073779

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001258A MXPA04001258A (es) 2001-08-10 2002-08-02 Activador para el receptor d que responde al proliferador de peroxisoma.

Country Status (16)

Country Link
US (3) US7265137B2 (es)
EP (1) EP1424330B1 (es)
JP (3) JP4421895B2 (es)
KR (1) KR100901683B1 (es)
CN (1) CN1330641C (es)
AT (1) ATE526319T1 (es)
AU (1) AU2002323776B2 (es)
BR (1) BRPI0211844B8 (es)
CA (1) CA2457054C (es)
CY (1) CY1112130T1 (es)
DK (1) DK1424330T3 (es)
ES (1) ES2372813T3 (es)
IL (2) IL160304A0 (es)
MX (1) MXPA04001258A (es)
PT (1) PT1424330E (es)
WO (1) WO2003016291A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
ATE526319T1 (de) 2001-08-10 2011-10-15 Nippon Chemiphar Co Aktivator für den peroxisome proliferator- responsiven rezeptor delta
IL161351A0 (en) * 2001-10-12 2004-09-27 Nippon Chemiphar Co ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR delta
WO2004093910A1 (ja) * 2003-04-22 2004-11-04 Astellas Pharma Inc. ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
DE602004022179D1 (de) 2003-09-19 2009-09-03 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
US7554974B2 (en) * 2004-03-09 2009-06-30 Tekelec Systems and methods of performing stateful signaling transactions in a distributed processing environment
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
ATE486055T1 (de) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
WO2006041197A1 (ja) * 2004-10-14 2006-04-20 Nippon Chemiphar Co., Ltd. ペルオキシソーム増殖剤活性化受容体δの活性化剤
EP1854784A1 (en) * 2005-02-28 2007-11-14 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator activating receptor
US20090203908A1 (en) * 2005-05-25 2009-08-13 Nippon Chemiphar Co., Ltd. Activator for Peroxisome Proliferator-Activated Receptor
AU2006265172B2 (en) 2005-06-30 2011-09-15 Vtv Therapeutics Llc Phenoxy acetic acids as PPAR delta activators
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
EP1931660B1 (en) * 2005-09-29 2012-08-01 Sanofi Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
PL2014652T3 (pl) * 2006-04-18 2015-02-27 Nippon Chemiphar Co Czynnik aktywujący receptor aktywowany przez proliferatory peroksysomów
AU2013202514B2 (en) * 2006-04-18 2015-09-17 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor delta
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
WO2007122970A1 (ja) * 2006-04-20 2007-11-01 Osaka University 核内受容体に結合するリガンド
AU2007309568A1 (en) 2006-10-20 2008-05-02 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2666310C (en) 2006-10-20 2012-07-31 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
FR2910893A1 (fr) * 2006-12-29 2008-07-04 Genfit Sa Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazolyl)-phenyl-propan-1-one substitues, preparations et utilisations.
ES2393424T3 (es) 2007-05-21 2012-12-21 Senju Pharmaceutical Co., Ltd. Agente farmacéutico que contiene un agonista de PPAR-delta
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
WO2009078981A2 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
JP5474769B2 (ja) 2008-04-15 2014-04-16 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体の活性化剤
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8497382B2 (en) 2008-12-01 2013-07-30 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
JP2012116753A (ja) * 2009-03-26 2012-06-21 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤活性化受容体の活性化剤
CN102724978A (zh) 2009-08-14 2012-10-10 塞伦尼斯治疗公司 用于治疗或预防炎症或能量代谢/产生相关疾病的PPARδ配体的用途
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN105237487B (zh) * 2015-10-19 2017-10-10 安徽中医药大学 含川芎嗪基查尔酮芳氧烷酸类化合物、制备方法及其应用
JPWO2017195875A1 (ja) * 2016-05-12 2019-03-22 日本ケミファ株式会社 創傷治療剤
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
JP3722855B2 (ja) * 1993-09-14 2005-11-30 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体およびそれを含んでなる医薬
GB9426448D0 (en) 1994-12-30 1995-03-01 Wellcome Found Process
US6043264A (en) 1995-01-06 2000-03-28 Toray Industries, Inc. Benzene-condensed heterocyclic derivatives and their uses
CA2171702A1 (en) 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
WO1996035688A1 (fr) 1995-05-08 1996-11-14 Nippon Chemiphar Co., Ltd. Derives de 2,4-thiazolidinedione ou d'oxazolidinedione et agent hypoglycemique
CN1209809A (zh) 1996-01-22 1999-03-03 藤泽药品工业株式会社 新化合物
ES2202582T3 (es) 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
US20020032330A1 (en) 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
ES2320181T3 (es) * 1997-07-24 2009-05-19 Astellas Pharma Inc. Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
US6589969B1 (en) 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU7073400A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
TWI260321B (en) * 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
AU2001277723A1 (en) 2000-08-11 2002-02-25 Nippon Chemiphar Co., Ltd. Ppardelta activators
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
WO2002076957A1 (fr) * 2001-03-23 2002-10-03 Nippon Chemiphar Co.,Ltd. Activateur de recepteur active par les proliferateurs du peroxysome
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
ATE526319T1 (de) * 2001-08-10 2011-10-15 Nippon Chemiphar Co Aktivator für den peroxisome proliferator- responsiven rezeptor delta

Also Published As

Publication number Publication date
IL160304A0 (en) 2004-07-25
BRPI0211844B8 (pt) 2021-05-25
ATE526319T1 (de) 2011-10-15
ES2372813T3 (es) 2012-01-26
CY1112130T1 (el) 2015-11-04
EP1424330A1 (en) 2004-06-02
DK1424330T3 (da) 2012-01-16
KR20040023741A (ko) 2004-03-18
US7648999B2 (en) 2010-01-19
JP2009280622A (ja) 2009-12-03
CA2457054A1 (en) 2003-02-27
IL160304A (en) 2010-12-30
CN1568316A (zh) 2005-01-19
BRPI0211844B1 (pt) 2019-08-27
WO2003016291A1 (fr) 2003-02-27
KR100901683B1 (ko) 2009-06-08
JPWO2003016291A1 (ja) 2004-12-02
US20080009631A1 (en) 2008-01-10
EP1424330A4 (en) 2004-10-27
US20050054674A1 (en) 2005-03-10
JP4421895B2 (ja) 2010-02-24
EP1424330B1 (en) 2011-09-28
CA2457054C (en) 2011-10-11
PT1424330E (pt) 2011-12-22
BR0211844A (pt) 2004-08-31
US20080009525A1 (en) 2008-01-10
US7265137B2 (en) 2007-09-04
JP2009102442A (ja) 2009-05-14
JP5097180B2 (ja) 2012-12-12
CN1330641C (zh) 2007-08-08
US7652045B2 (en) 2010-01-26
AU2002323776B2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
MXPA04001258A (es) Activador para el receptor d que responde al proliferador de peroxisoma.
DE60232739D1 (de) Aktivator des peroxisomproliferator-aktivierten rezeptors delta
HK1072770A1 (en) Bicyclic compound
GB0123589D0 (en) Organic compounds
GB0129476D0 (en) Organic compounds
MX2007006690A (es) Analogos 12-aril de prostaglandina.
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
DE60223904D1 (de) Benzylaminanalogen
YU33202A (sh) Jedinjenja o-etar oksima i fungicidi za primenu u zemljoradnji i vrtlarstvu
TR200100740T2 (tr) Tiyazolilsinnamonitriller ve haşere kontrol edici ajanlar
EP1295868A4 (en) AMID COMPOUNDS AND THEIR USE
IL170056A (en) Pyrazole compounds
DE60113808D1 (de) Therapeutikum oder Prophylaktikum für Lebererkrankungen, enthaltend ein Diaminotrifluorethylpyridin-Derivat
EP1197211A4 (en) CANCER PREVENTION AND TREATMENT ACTIVE INGREDIENTS
EP1557407A4 (en) NEW ALPHA-CETOAMIDE DERIVATIVE AND USE THEREOF

Legal Events

Date Code Title Description
FG Grant or registration